Global expansion readiness Sanovel has EU GMP certification and FDA approval with an ambition to become a global pharmaceutical company, indicating openness to international partnerships, licensing, and co-development opportunities beyond Türkiye.

Robust R&D moat With a strong R&D orientation, extensive IP, and a patent-leading position in Türkiye, there are clear avenues for partnerships in novel formulations, new chemical entities, and technology licensing to accelerate product pipelines.

Large scale capacity An annual production capacity of 227 million units and a sizable workforce enables scalable manufacturing collaborations, contract manufacturing, and large‑volume distribution agreements to support partners’ market reach.

Diversified portfolio Over 60 brands and 180 products across multiple therapeutic areas create cross-sell potential and opportunities to bundle products, expand existing channels, and enter new market segments via co‑marketing strategies.

Strategic partnerships Existing licensing activity, such as the PharmaMar collaboration for Yondelis in Turkey, demonstrates a willingness to engage in international deals, licensing, and strategic alliances that can be leveraged for future BD opportunities.